Immunohistochemical analysis was performed on formalin-fixed, paraffin embedded liver tissue microarrays. The tissue microarrays contained non-cancer tissues matching to (lower row). Data show 6 different sections (3 each from non-cancerous and cancer tissues). The Myeloid-Assoc. Differentiation Marker polyclonal antibody (Product # PA1-41578) was used at 1:400 dilution.
|Tested species reactivity||Dog, Human, Non-human primate, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide corresponding to residues 250-300 of human MYADM.|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS with 0.2% BSA|
|Contains||0.05% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||5-10 µg/ml|
|Western Blot (WB)||0.2-1 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
This antibody is predicted to react with human, bovine, mouse and chimpanzee based on sequence homology.
MYADM, belonging to the MAL family, is a 322-amino acid protein having 7 hydrophobic transmembrane domains, several potential consensus sites for phosphorylation and sequence homology with the T-cell differentiation protein MAL and plasmolipin. It shares 75.8% sequence identity with mouse in the transmembrane regions and is associated with differentiation of hematopoietic cells or acute promyelocytic leukemia cells. Its expression is up-regulated in NB4 cells induced by all-trans retinoic acid whereas down regulation inhibits colony formation of bone marrow cells. MYADM could serve as a new marker for hematopoietic differentiation and is a target for diagnostic, prognostic and/or therapeutic interventions. It is known to express widely in brain and pancreatic islet cells.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.